Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial

Journal of Clinical Oncology

Volumn 20, Issue 12, 2002, Pages 2824-2831

  Hensley, Martee L ^a   Maki, Robert ^a   Venkatraman, E ^a   Geller, Gennifer ^a   Lovegren, Meghan ^a   Aghajanian, Carol ^a   Sabbatini, Paul ^a   Tong, William ^a   Barakat, Richard ^a   Spriggs, David R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; LEIOMYOSARCOMA; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEIOMYOSARCOMA; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; TAXOIDS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 0037096747     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.050     Document Type: Article

References (46)

1. Prognostic factors in early stage uterine sarcoma
2. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine sarcoma
3. Resection of pulmonary metastases from uterine sarcomas
4. Uterine/female genital sarcomas: Current treatment
5. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: A Gynecologic Oncology Group study
6. Mitoxantrone in the treatment of advanced uterine sarcoma
7. Amonafide in patients with leiomyosarcoma of the uterus
8. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study
9. A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus: A Gynecologic Oncology Group study
10. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: A phase II study of the Gynecologic Oncology Group
11. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study
12. Phase Il trial of etoposide in the management of advanced or recurrent leiomyosarcoma of the uterus: A Gynecologic Oncology Group study
13. A randomized study of Adriamycin with and without dimethyl triazenolimidazole carboxamide in advanced uterine sarcomas
14. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: A Gynecologic Oncology Group study
15. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: A Gynecologic Oncology Group study
16. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′2′-difluorodeoxycytidine
17. Action of 2′2′-difluorode-oxycytidine on DNA synthesis
18. Preclinical characteristics of gemcitabine
19. Combination studies with gemcitabine in the treatment of non-small-cell lung cancer
20. Studies with RP-56976 (Taxotere): A semi-synthetic analogue of Taxol
21. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
22. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
23. Gemcitabine: Preclinical pharmacology and mechanisms of action
24. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
25. Pharmacologically directed design of the dose rate and schedule of 2′2′-difluorodeoxycytidine (gemcitabine) administration in leukemia
26. Saturation of 2′2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
27. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
28. Action of 2′2′-difluorode-oxcytidine on DNA synthesis
29. Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinical study in dogs
30. Validated assays for the determination of gemcitabine in human plasma and using high-performance liquid chromatography with ultraviolet detection
31. Optimal two-stage designs for phase II clinical trials
32. Progression free rate as the principal end-point for phase II trial on soft tissue sarcoma: What should be the target? A retrospective study of the EORTC soft tissue and bone sarcoma (STBSG) database
33. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult: EORTC Soft Tissue and Bone Sarcoma Group
34. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced of metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer and Soft Tissue and Bone Sarcoma Group
35. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation
36. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma
37. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
38. Single-agent activity of weekly gemcitabine advanced non-small-cell lung cancer: A phase II study
39. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre extended phase II study
40. Docetaxel (Taxotere) is active in non-small cell lung cancer: A phase II trial of EORTC Early Clinical Trials Group (ECTG)
41. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer
42. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: A Japanese cooperative study
43. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies